Pulmonary Sarcoidosis
Respiratory
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
aTyr PharmaSAN DIEGO, CA
2 programs1
1
Efzofitimod 3 mg/kgPhase 31 trial
Efzofitimod 1.0 mg/kg or PlaceboPhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
aTyr PharmaEfzofitimod 3 mg/kg
MolecureOATD-01
aTyr PharmaEfzofitimod 1.0 mg/kg or Placebo
Clinical Trials (3)
Total enrollment: 305 patients across 3 trials
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Start: Sep 2022Est. completion: Aug 2025268 patients
Phase 3Active Not Recruiting
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
Start: Mar 2024Est. completion: Sep 2027
Phase 2Recruiting
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
Start: Jan 2019Est. completion: Jun 202137 patients
Phase 1/2Completed
Related Jobs in Respiratory
Regional Gene Therapy Consultant - Upper Midwest (IL/WI/MN)
Krystal Biotech
1h ago
$185K - $215K/yr
Regional Gene Therapy Consultant - Southwest (CO/AZ/NM/UT)
Krystal Biotech
1h ago
$185K - $215K/yr
Ausbildung zum Pharmakanten (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
Yesterday
Marketing Intern – Vertex Iberia (Spain)
Vertex Pharmaceuticals
Madrid, Spain
Yesterday
Sales Rep Neurology Region Leipzig, Halle, Gera, Jena, Weimar DE_G2M110105 - befristet bis 31.03.2027 (all genders)
Sanofi
Berlin
Yesterday
Laboratory Assistant (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
2d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 305 patients
2 companies competing in this space